新型内酰胺类化合物作为治疗轴突退变的SARM1抑制剂
Novel Lactams as SARM1 Inhibitors for Treating Axonal Degeneration.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 May 9;16(6):931-932. doi: 10.1021/acsmedchemlett.5c00241. eCollection 2025 Jun 12.
Abstract
Provided herein are novel lactams as SARM1 inhibitors, pharmaceutical compositions, use of such compounds in treating axonal degeneration and processes for preparing such compounds.
摘要
本文提供了作为SARM1抑制剂的新型内酰胺、药物组合物、此类化合物在治疗轴突退变中的用途以及制备此类化合物的方法。
相似文献
1
Novel Lactams as SARM1 Inhibitors for Treating Axonal Degeneration.新型内酰胺类化合物作为治疗轴突退变的SARM1抑制剂
ACS Med Chem Lett. 2025 May 9;16(6):931-932. doi: 10.1021/acsmedchemlett.5c00241. eCollection 2025 Jun 12.
2
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.新型取代内酰胺类化合物作为5-HT1A激动剂用于治疗神经精神疾病。
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
3
SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders.SARM1：神经系统疾病中轴突退化的检查点。
Mol Neurobiol. 2025 Mar 17. doi: 10.1007/s12035-025-04835-3.
4
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
5
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
6
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
7
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2025 Apr 1;16(4):538-539. doi: 10.1021/acsmedchemlett.5c00143. eCollection 2025 Apr 10.
8
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.新型化合物作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Apr 26;16(5):760-761. doi: 10.1021/acsmedchemlett.5c00218. eCollection 2025 May 8.
9
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
10
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
本文引用的文献
1
Fat traffic control: S-acylation in axonal transport.脂肪运输调控：轴突运输中的S-酰化作用
Mol Pharmacol. 2025 Jun;107(6):100039. doi: 10.1016/j.molpha.2025.100039. Epub 2025 Apr 16.
2
SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders.SARM1：神经系统疾病中轴突退化的检查点。
Mol Neurobiol. 2025 Mar 17. doi: 10.1007/s12035-025-04835-3.
3
Augustus Waller's foresight realized: SARM1 in peripheral neuropathies.奥古斯都·沃勒有先见之明：SARM1 在周围神经病变中的作用。
Curr Opin Neurobiol. 2024 Aug;87:102884. doi: 10.1016/j.conb.2024.102884. Epub 2024 Jun 8.
4
Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.引导烟酰胺磷酸核糖转移酶（NAMPT）来应对生死问题。
J Med Chem. 2024 Apr 25;67(8):5999-6026. doi: 10.1021/acs.jmedchem.3c02112. Epub 2024 Apr 5.
5
Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives.腓骨肌萎缩症 2A 型：发病机制和治疗前景的最新进展。
Neurobiol Dis. 2024 Apr;193:106467. doi: 10.1016/j.nbd.2024.106467. Epub 2024 Mar 5.
Zotero 插件